These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9107262)

  • 1. Screening for prostate cancer.
    Swales J; Winyard G
    Lancet; 1997 Apr; 349(9058):1098. PubMed ID: 9107262
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening for prostate cancer.
    Woolf SH
    Lancet; 1997 Apr; 349(9058):1098-9. PubMed ID: 9107263
    [No Abstract]   [Full Text] [Related]  

  • 3. The prostate question, unanswered still.
    Lancet; 1997 Feb; 349(9050):443. PubMed ID: 9040566
    [No Abstract]   [Full Text] [Related]  

  • 4. Upcoming evidences on prostate-specific antigen-based screening for men at risk of prostate cancer.
    Boscolo-Berto R
    Int J Urol; 2009 Sep; 16(9):711. PubMed ID: 19769655
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostate cancer screening: what we know, don't know, and believe.
    Brawley OW
    Ann Intern Med; 2012 Jul; 157(2):135-6. PubMed ID: 22801675
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate-specific antigen screening for prostate cancer: why so much controversy?
    Labrie F
    Int J Urol; 2013 Nov; 20(11):1148. PubMed ID: 23586435
    [No Abstract]   [Full Text] [Related]  

  • 7. The jury is still out with regard to screening for the prostate cancer with prostate-specific antigen.
    Eur J Cancer Care (Engl); 2002 Jun; 11(2):78. PubMed ID: 12168606
    [No Abstract]   [Full Text] [Related]  

  • 8. Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?
    Jackson BR
    Arch Pathol Lab Med; 2013 Mar; 137(3):308-9. PubMed ID: 22799565
    [No Abstract]   [Full Text] [Related]  

  • 9. [Opportunity for a systematic screening of prostatic cancer by determining prostate specific antigen levels].
    Cuzin B; Maisonneuve H; Thoral F; Charvet-Protat S
    Prog Urol; 2000 Feb; 10(1):124-7. PubMed ID: 10785932
    [No Abstract]   [Full Text] [Related]  

  • 10. A risk-stratified approach to prostate-specific antigen screening.
    Keto CJ; Freedland SJ
    Eur Urol; 2011 Apr; 59(4):506-8. PubMed ID: 21292387
    [No Abstract]   [Full Text] [Related]  

  • 11. Summaries for patients. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
    Ann Intern Med; 2012 Jul; 157(2):I-44. PubMed ID: 22801691
    [No Abstract]   [Full Text] [Related]  

  • 12. Weighing the benefits and downsides of prostate-specific antigen screening.
    Pignone M
    Arch Intern Med; 2009 Sep; 169(17):1554-6. PubMed ID: 19786672
    [No Abstract]   [Full Text] [Related]  

  • 13. [The significance and limitation of prostate specific antigen in the mass screening for prostate cancer].
    Imai K; Yamanaka H
    Nihon Rinsho; 1998 Aug; 56(8):1994-7. PubMed ID: 9750494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation.
    Catalona WJ; D'Amico AV; Fitzgibbons WF; Kosoko-Lasaki O; Leslie SW; Lynch HT; Moul JW; Rendell MS; Walsh PC
    Ann Intern Med; 2012 Jul; 157(2):137-8. PubMed ID: 22801676
    [No Abstract]   [Full Text] [Related]  

  • 15. [Screening for prostate cancer: results from the first screening round in the French population of the ERSPC trial].
    Richard F
    Prog Urol; 2009 Jul; 19(7):499-500. PubMed ID: 19559381
    [No Abstract]   [Full Text] [Related]  

  • 16. Screening for prostate cancer remains controversial.
    Neal DE; Donovan JL; Martin RM; Hamdy FC
    Lancet; 2009 Oct; 374(9700):1482-3. PubMed ID: 19664817
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate cancer screening.
    Catalona WJ
    BJU Int; 2004 Nov; 94(7):964-6. PubMed ID: 15541107
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostate specific antigen testing for the diagnosis of prostate cancer.
    McKenzie P; Delahunt B; deVoss K; Ross B; Tran H; Sikaris K
    Pathology; 2011 Aug; 43(5):403. PubMed ID: 21753713
    [No Abstract]   [Full Text] [Related]  

  • 19. Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer.
    Loeb S; Carter HB
    Urol Oncol; 2009; 27(6):583-4. PubMed ID: 19879470
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?
    Carroll PR; Whitson JM; Cooperberg MR
    J Clin Oncol; 2011 Feb; 29(4):345-7. PubMed ID: 21189396
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.